Keiser, Megan S.
Ranum, Paul T.
Yrigollen, Carolyn M. http://orcid.org/0000-0002-2399-6176
Carrell, Ellie M.
Smith, Geary R.
Muehlmatt, Amy L.
Chen, Yong Hong
Stein, Joel M.
Wolf, Ronald L.
Radaelli, Enrico http://orcid.org/0000-0002-2885-0221
Lucas, Timothy J. II
Gonzalez-Alegre, Pedro
Davidson, Beverly L. http://orcid.org/0000-0002-3715-6290
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (UH3-NS094355, UH3-NS094355, UH3-NS094355, UH3-NS094355)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32HG009495)
Article History
Received: 28 September 2020
Accepted: 30 August 2021
First Online: 18 October 2021
Competing interests
: B.L.D. is a founder of Spark Therapeutics and Spirovant Sciences. She serves an advisory role and/or receives sponsored research support for her laboratory from Roche, NBIR, Homology Medicines, Triplet Therapeutics, Resilience, Intellia Therapeutics, Spirovant Sciences, Panorama Medicines and Voyager Therapeutics. P.G.-A. has consulted for Eisai Therapeutics, Spark Therapeutics and NeuExcell Therapeutics. The remaining authors declare no competing interests.